For example, studies have demonstrated that luteolin reduces osteosarcoma chemotherapy resistance by upregulating miR-384 expression and inhibiting the PTN/β-catenin/MDR1 signaling axis, with exosomal miR-384 being transferred to recipient osteosarcoma cells, thereby inhibiting doxorubicin resistance [136]. Here, PTN is linked to osteosarcoma.